Adaptimmune Therapeutics PLC Income Statement
ADAPY|9 years of annual SEC 10-K data (FY2016-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
Adaptimmune Therapeutics PLC reported $178M in revenue and $71M in net loss for FY2024. Revenue has grown at a 37.2% compound annual rate over the past 8 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $178.0M | $60.3M | $27.1M | $6.1M | $4.0M | $1.1M | $59.5M | $37.8M | $14.2M |
| Cost of Revenue | $70.0K | - | - | - | - | - | - | - | - |
| SG&A Expense | $87.3M | $73.5M | $63.4M | $57.3M | $45.8M | $43.4M | $43.6M | $31.1M | $23.2M |
| R&D Expense | $149.1M | $126.5M | $127.7M | $111.1M | $91.6M | $97.5M | $98.3M | $87.4M | $63.8M |
| Operating Income | -$68.8M | -$139.7M | -$164.0M | -$162.2M | -$133.4M | -$139.8M | -$82.4M | -$80.7M | -$72.8M |
| Income Tax | $3.6M | $1.3M | $2.5M | $791.0K | $162.0K | $242.0K | $497.0K | $451.0K | $892.0K |
| Net Income | -$70.8M | -$113.9M | -$165.5M | -$158.1M | -$130.1M | -$137.2M | -$95.5M | -$70.1M | -$71.6M |
| EPS (Basic) | -$0.17 | -$0.17 | -$0.15 | -$0.22 | - | - | - | - | - |
| EPS (Diluted) | -$0.17 | -$0.17 | -$0.15 | -$0.22 | -$0.16 | -$0.16 | -$0.17 | -$0.17 | -$0.08 |
| Shares Outstanding | 1.4B | 987.1M | 928.5M | 928.8M | 631.0M | 627.5M | 562.1M | 424.8M | 424.7M |
| Operating Margin | -38.6% | -231.8% | -604.0% | -2638.6% | -3370.5% | -12457.2% | -138.4% | -213.2% | -512.7% |
| Profit Margin | -39.8% | -188.9% | -609.5% | -2571.0% | -3286.8% | -12225.0% | -160.5% | -185.4% | -504.2% |